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Optimization of the physical and physiological parameters of the fermentation process using the gene 
amplified variant of Amycolatopsis mediterranei (NCH) was carried out. Optimization of the physical 
parameters by controlling the pH at 6.5 for 3 days then at 7 thereafter and by adjustment of aeration at 1 
vvm for 3 days then controlling the dissolved oxygen (DO) at 30% saturation  increased the yield from 
9.77 to 11.96 (22%) and 13.39 g/l (37%), respectively.  Replacing 12% glucose in the fermentation 
medium (F2m1) with 5% glucose syrup (F2m3 medium) resulted in a drop of the yield from 9.77 to 7.5 
g/l, while further addition of another 5% glucose syrup at day 4 increased the yield from 7.5 to 13.81 g/l 
(84%); with a further increase in the yield to 14.25 g/l (90%) upon controlling DO. Whereas, the 
combined addition of 0.1% yeast extract at day 2  to F2m3 medium along with the addition 5% glucose 
syrup at day 4 increased the yield from 7.5  to 15.35 g/l (105%); with a further increase in the yield to 
16.3 g/l (117%) upon controlling DO. The fed-batch addition of both 3% soytone at day 3 and 5% of 
glucose syrup at day 4 to F2m3 medium increased the yield from 7.5 to 16.2 g/l (116%) and by extending 
the fermentation period to 10 days the yield reached 17.9 g/l (139%). Upon applying all optimum 
physical and physiological conditions in the fermentor the yield increased from 7.5 to 17.43 g/l in 8 days 
(132%) and by extending the fermentation period to 10 days the yield reached 19.4 g/l (159%). Further 
process optimization by examination and analysis of the kinetics of the process would most certainly 
further increase the yield and quantitatively define the process to a level that could be tested on a pilot 
scale.  
 






In recent years, rifamycins have acquired an added 
significance all over the world. Although rifamycins are 
primarily used against Mycobacterium tuberculosis and 
M. leprae, they are also effective against M. avium 
associated with acquired immunodeficiency diseases and 
penicillin-resistant pneumococci (Anon, 1999; Anne et al., 
2000; Reynaldo-Dietze et al., 2001 and Russell, 1998).  
 
 
*Correspondingauthor. E-Mail: omtayeb@link.net. 
In view of this importance, Amycolatopsis mediterranei 
has been the focus of research of many laboratories. 
Yields of rifamycins vary from a few milligrams per liter to 
as high as 15 g/l. Fermentation processes and 
fermentation media have been continuously updated to 
obtain better yields of rifamycin (Lancini and Hengeller, 
1971; Ghisalba et al., 1984; Lysko and Gorskaia, 1986; 
Schupp and Divers 1986; Chiao et al., 1988; Lal et al., 
1995; Lancini and Cavalleri, 1997 and Venkateswarlu et 






and agitation may have a substantial effect on the 
antibiotic production. Optimization of antibiotic production 
necessitates studying of the different physical and 
physiological factors affecting its production; taking into 
concern that the optimal fermentation conditions are 
related to the strain used (Pape and Rehm, 1985 and 
Venkateswarlu et al., 2000). For fermentation, A. 
mediterranei is first grown in seed medium, and then 
cultures are transferred to production medium. The use of 
reasonably cheaper ingredients in the production medium 
considerably lowers the production cost of rifamycin. 
Thus, several manipulations of the media, such as 
replacement of the costly carbon source, glucose, by 
cheaper ingredients such as maize flour, peanut meal 
and glycerol have been attempted (Ghisalba et al., 1984; 
Lal et al., 1995).  
This study aimed at improvement of the fermentation 
process parameters to achieve better yield of rifamycin B 
and to lower the cost of production. Thus, we applied the 
optimized process previously developed in shake flasks 
(El Tayeb et al., 2004 bc) on fermentation experiments 
carried out in laboratory fermentors. The significant 
parameters that govern the fermentation process, such 
as aeration, dissolved oxygen, pH and the composition of 
the fermentation medium as well as the different regimes 
of fed-batch of some fermentation medium components 
were studied.  
 
 
MATERIALS AND METHODS 
 
Bacterial strain  
 
The amplified variant NCH of Amycolatopsis mediterranei–RCP 
1001,  previously obtained as described by El-Tayeb et al. (2004a) 
was maintained on Q/2 agar slants and stored at 4°C to be used 
within 27 days. For long-term storage, the surface growth on Q/2 





Chemicals used throughout this work were of laboratory reagent 
grade, unless otherwise indicated. Glucose, NH4NO3 and NaNO2 
were the products of ADWIC, Egypt. Sodium diethyl barbiturate 
(SDB) was the product of Grindstedvaerket A/S, Denmark. 
Potassium sodium tartarate tetrahydrate, 3,5_dinitrosalicylic acid, 
CaCO3, MgSO4.7H2O, KH2PO4, HCl and NaOH were the products 
of E. Merck, Darmstadt, Germany. Glacial acetic acid was the 





Yeast extract, malt extract, beef extract, soytone, tryptone, skim 
milk and bacto agar were the products of Difco Laboratories, 
Detroit, U.S.A. Sunflower oil and oat flakes were obtained from 
commercial suppliers. Glucose syrup was obtained from the 
Egyptian Co. for Production of Starch and Glucose, Cairo. 
Media used for propagation, selection and maintenance as well 
as the vegetative medium V2 and the fermentation medium F2m1 
were those previously reported by El-Tayeb et  al.  (2004a,  b).  The  




modified fermentation medium F2m3 is composed of: glucose syrup 
50.0 g, 120.0 g; soytone,      30.0 g; NH4NO3, 1.0 g; KH2PO4, 1.0 g; 
CaCO3, 8.5g; MgSO4.7H2O, 0.8 g;  sodium diethyl barbiturate, 1.0 g 





The methods used for maintenance, propagation, selection and 
preparation of inoculum as well as determination of remaining 
glucose or reducing sugars concentration, biomass and assay of 




Production of rifamycin B in the fermentor  
 
The production of rifamycin B was carried out in a 6.6 litre 
laboratory glass fermentor (Bioflo 3000 Benchtop fermentor, New 
Brunswick Scientific Co., NJ, USA). The inoculum in a 
concentration of 5% was added to 2.5 litres of F2m1 medium, 
unless otherwise indicated. Agitation was carried out using 2 six 
blade Rushton impeller separated by 9.5 cm with the lower impeller 
2.5 cm above the agitator tip. Aeration using a multiorifice ring 
sparger was controlled by a pressure regulator and monitored by a 
flowmeter. The percent dissolved oxygen (DO) was monitored 
and/or controlled through the fermentor’s control unit using 
polarographic DO probe. DO control was achieved by cascading 
the airflow and the agitation speed simultaneously. The pH was 
monitored by a pH electrode; calcium carbonate was omitted from 
the medium when the pH was automatically controlled by the 
fermentor’s control unit, which applied 1N HCl, and 1N NaOH 
actuated by peristaltic pumps. The temperature was adjusted at 
28°C, the agitation rate at 500 rpm and the aeration rate at 1 vvm, 
unless otherwise indicated. Foam was suppressed by sterile 
sunflower oil using a foam controller pump and a foam probe. 
Samples were taken every 24 h and rifamycin B concentration, 
remaining glucose or reducing sugars concentrations, dry cell 
weight and, where indicated, viscosity of the broth mixture was 
determined. For fed-batch experiments, aliquots of 150 ml of 
glucose, 150 ml of glucose syrup, 150 ml of soytone, 25 ml of yeast 
extract were taken from sterile stock solutions containing suitable 
concentrations,  and added to the fermentation culture at the 
indicated times to give the required final concentrations. 
 
 
Determination of viscosity 
 
Ten ml of the fermentation broth culture were placed in the small 
adaptor of the rotational viscometer (Cole-Parmer 98936, USA). 
The spindle and speed combination was carefully selected to 
measure the correspondent viscosity in centipoise (cp) according to 
the table present in the instruction and operation manual supplied 





By applying the process previously developed in shake 
flasks (El-Tayeb et al. 2004a, b) using F2m1 medium on 
fermentation experiments carried out in the fermentor 
(operated at 1 vvm, 500 rpm and 28°C) with NCH strain, 
the yield decreased from 11.76 to 9.77 g/l (Figure 1). 
Different manipulations of the fermentation process were 
carried out in batch-mode by changing the aeration rate, 
dissolved oxygen and pH or the application of fed-batch 
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Figure 2. Effect of aeration rate on rifamycin B production (P), biomass (X) and viscosity in F2m1 medium by variant 
NCH. Conditions: 500 rpm and 28°C. 
 
 
mode by the addition of glucose syrup, yeast extract and 
soytone, as described below. 
The effect of the use of aeration rates of 0.5, 1 and 2 
vvm on rifamycin B production, dry cell weight and 
viscosity is illustrated in Figures 1 and 2. Maximum 
rifamycin B production was obtained upon using 1 vvm 
9.77 g/l) followed by 0.5 vvm (7.5 g/l) then 2 vvm (4.7 g/l), 
while the highest viscosity was obtained upon using 
aeration rate of 2 vvm followed by 1 vvm then 0.5 vvm. 
Different regimes for controlling DO were tested (Figure 
3). The best regime was the use of 1 vvm for 3 days, then 
controlling   DO   at   30%   saturation   to    the    end    of  
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(P) 1 vvm (X) 1 vvm
(P) 30% DO (X) 30% DO
(P) 1 vvm for 3 days then  30% DO (X) 1 vvm for 3 days then  30% DO 
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(P) 1vvm for 3 days then 60%DO (X) 1vvm for 3 days then 60% DO
(P) pH 6.5 for 3 days then 7 (X) pH 6.5 for 3 days then 7  
 
Figure 3. Effect of controlling DO and pH on rifamycin B production (P), and biomass (X) by variant NCH in F2m1 medium. Conditions: 500 
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Figure 4. Effect of replacing 12% glucose in F2m1 medium by 5% glucose syrup (F2m3) on process parameters by variant NCH. Conditions: 
1 vvm, 500 rpm, pH 6.5 for 3 days then 7 and 28°C. 
 
 
fermentation, where the yield increased from 9.77 to 
13.39 g/l (37%). Controlling the pH at 6.5 for 3 days then 
at 7 to the end of the fermentation process (Figure 3) 
increased rifamycin B production from 9.77 to 11.96 g/l 
(22%).The effect of the replacement of glucose in F2m1 
medium  with  5%  glucose   syrup   (F2m3)   on   process  
 
parameters is illustrated in Figure 4. The use of F2m3 
decreased rifamycin B production from 9.77 to 7.5 g/l. 
Different regimes of fed-batch addition of glucose syrup 
to F2m3 were tested (Figure 5). All the tested regimes 
increased rifamycin B production from 7.5 g/l to a yield 
ranging from 12.94 g/l to 13.81 g/l (73 to 84%).  The  best  
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(P) F2m3 (X) F2m3
(P) F2m3+ 5% G.S. at day 4 (X) F2m3+ 5% G.S. at day 4
(P ) F2m3+ 5 + 5% G.S. at days  4 & 6 (X) F2m3+ 5 + 5% G.S. at days 4 & 6
(P) F2m3+ 2.5 + 5% G.S. at days 0 & 4 (X) F2m3+ 2.5+ 5% G.S. at days 0 & 4
(P) 12% glucose (X) 12% glucose
 
 
Figure 5. Effect of different regimes for addition of glucose syrup (G.S.) to F2m3 medium on rifamycin B production (P) and biomass (X) by 




regime was the addition of 5% glucose syrup at day 4 
where the yield increased from 7.5 to 13.81 g/l (84%) with 
a further increase to 14.25 g/l (90%) upon applying the 
optimum regime for controlling DO (Figure 5). Whereas, 
the combined addition of 0.1% yeast extract at day 2 
along with the addition of 5% glucose syrup at day 4 
(Figure 6) increased the yield from 7.5 to 15.35 g/l 
(105%); with a further increase to 16.3 g/l upon using the 
best regime for controlling DO (117%). While, the 
combined addition of 3% soytone at day 3 along with the 
addition of 5% glucose syrup at day 4 (Figure 6) 
increased the yield from 7.5 to 16.2 g/l (116%) and by 
extending the fermentation period to 10 days, the yield 
reached 17.9 g/l (139%). 
Integration of the optimum physical and physiological 
conditions was carried out in the fermentor (Figure 7). By 
applying the fed-batch addition of 0.1% yeast extract at 
day 2, 3% soytone at day 3 and 5% glucose syrup at day 
4 to F2m3 medium under the best regime of controlling 
pH and DO,  the  yield  increased  from  7.5  to  17.43  g/l  
 
(132%) and by extending the fermentation period to 10 





The results of production of aerobic fermentation on 
products in shake flasks usually could not be 
extrapolated to indicate possible performance in the 
fermentor (Dewitt et al., 1989). Both physical and 
biological factors are quite different in fermentors and in 
shake flasks. Moreover, controls on the reaction in the 
shake flasks are extremely limited while in the fermentor 
such controls are almost limitless. Accordingly, results 
obtained in the shake flasks should be taken only as 
preliminary indicators for the conditions necessary for 
successful industrial production and must be verified in 
studies carried out in the fermentor. For large-scale 
fermentation, the use of reasonably cheaper ingredients 
in the production medium considerably lowers the cost  of  
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(P) F2m3 (P) F2m3+ 5% G.S., day 4
(P)  F2m3+ 5% G.S., day 4+ DO control (P) F2m3+ 5% G.S., day4+ 0.1% Y.E., day2
(P) F2m3+ 5% G.S. day4+ 0.1% Y.E., day2+ DO control (P) F2m3+ 5% G.S., day 4+ 3% soytone, day 3
(X) F2m3 (X) F2m3+ 5% G.S., day 4
(X)  F2m3+ 5% G.S., day 4+ DO control (X) F2m3+ 5% G.S., day 4+ 0.1% Y.E., day2
(X)  F2m3+ 5% G.S., day4+ 0.1% Y.E., day2+ DO control (X) F2m3+ 5% G.S., day4+ 3%soytone, day3  
 
Figure 6. Effect of fed-batching  5% glucose syrup (G.S.) at day 4 alone or combined with either 0.1% yeast extract (Y.E.) at day 2 or 3% 
soytone at day 3, to F2m3 and of controlling DO (1vvm for 3 days then 30% DO) on rifamycin B production (P) and biomass (X) by variant 
NCH. Conditions: 1 vvm , 500 rpm, pH 6.5 for 3 days then 7 and 28°C. 
 
 
production. Thus, several manipulations of the F2 
medium by the use of a lower concentration of soytone 
(3% instead of 3.5%) and the replacement of (NH4)2SO4 
by the more productive and cheaper NH4NO3 (F2m1) or 
along with the replacement of the costly carbon source, 
glucose, by the cheaper glucose syrup (F2m3) as well as 
studying the influence of different physical and 
physiological parameters have been attempted in a 
fermentor.  
By applying the process previously developed in shake 
flasks (El-Tayeb et al., 2004a, b) using F2m1 medium on 
fermentation experiments carried out in the fermentor 
(operated at 1 vvm, 500 rpm and 28°C) with NCH strain, 
the yield decreased from 11.76 to 9.77 g/l (Figure1). This 
lower yield observed upon using the fermentor was in 
accordance with the findings of Alvarez et al. (1990), who 
observed that there were both qualitative and quantitative 
differences in the production of rifamycin under shake 
flask and pilot-scale fermentations. In shake flasks, only 
rifamycin B was produced while in fermentors both 
rifamycin B and W were produced, with the production 
rate of rifamycin B decreasing with the accumulation of 
rifamycin W. They did not explain this difference in 
behavior of the strain in shake flasks and fermentors. 
Aeration has an important effect on rifamycin B prod-
uction. A characteristic of A. mediterranei fermentation is 
the very high oxygen requirement in a definite period of 
the growth-production cycle. The time at which this 
occurs varies with the strain and the medium 
composition, but it always coincides with the phase in 
which glucose is rapidly metabolized. If this oxygen 
demand is not met by an adequate oxygen supply 
through aeration, a very low final yield of rifamycin B is 
obtained (Virgilio et al., 1964 and Lancini and Cavalleri, 
1997). In several reports, airflow of 1 vvm is carried out at 
pilot scale (Lee et al., 1983; Lee and Rho, 1994 and 
Lancini and Cavalleri, 1997). In our study, the maximum 
rifamycin B production was obtained (Figures 1 and 2) 
upon using 1 vvm (9.77 g/l) followed by the use of 0.5 
vvm (7.5 g/l) then by the use of 2 vvm (4.7 g/l). Therefore,  
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Figure 7. Effect of fed-batching  0.1% yeast extract at day 2, 3% soytone at day 3 and 5% glucose syrup at day 4 to F2m3 with controlling pH 




1 vvm was selected for further fermentation studies 
performed in the fermentor. The lowest yield of rifamycin 
B obtained upon using 2vvm was associated with the 
highest biomass and consequently the highest viscosity 
(Figure 2). This cell mass exceeded the level that can be 
supported by the optimum oxygen transfer rate (OTR) 
required for maximum antibiotic production in the 
fermentor as reported by Margaritis and Zajic (1978).  
It was also observed that, in experiments using 1 vvm 
or 0.5 vvm, the recorded dissolved oxygen decreased to 
zero on the 3rd (Figure 1) or 4th day (data not shown) of 
fermentation process and remained so till the end of 
fermentation period. Based on this result and taking in 
consideration the reported 30% saturation as a minimum 
oxygen demand for growth and production phases (Lee 
and Rho, 1994), we tried different regimes of controlled 
dissolved oxygen (Figure 3) to maintain optimal DO level 
throughout the fermentation. A marked increase in the 
yield from 9.77 to 13.39 g/l (37%) was achieved by using 
1 vvm for 3 days then 30% controlled DO to the end of 
the fermentation period (Figure 3).  
Controlling the pH during the fermentation has been 
reported to contribute to improving rifamycin B 
production. Thus, Lee et al. (1983) reported a 
characteristic pH behavior pattern of A. mediterranei and 
recommended a pH strategy of 6.5 at the trophophase 
(day 1-3) and 7.0 at the idiophase (day 4-8). This pH 
profile was applied and this increased the yield of 
rifamycin B (Figure 3) from 9.77 g/l to 11.86 g/l (22%). 
To lower the production cost of rifamycin B, the 
cheaper glucose syrup was used instead of the costly 
carbon source, glucose, in the F2m3 medium. From the 
results using shake flasks (El-Tayeb et al., 2004a), we 
have already found that 5% glucose syrup was the lowest 
optimum concentration for both growth and production of 
rifamycin B. In the fermentor, the yield of rifamycin B 
upon using 5% glucose syrup under controlled pH was 
7.5 g/l (Figure 4) compared to 11.96 g/l when using 12% 
glucose (Figure 5). This reduction may be attributed to 
the low glucose content in glucose syrup. The glucose 
syrup used is a product of an acid hydrolysis process and 
contains less than 25% of its carbohydrates in the form of 
glucose, the remaining carbohydrates being a mixture of 
disaccharides, trisaccharides and dextrins; the response 
of the organism to which is not known. This fact is further 
supported by the observation that with 5% glucose syrup 
in the fermentor there was clear carbon starvation as 
evidenced by the exhaustion of the used carbon source 
to less than 0.15% on day 4 (Figure 4). Since the 
utilization of glucose at the idiophase influences rifamycin 
B production (Lee et al., 1983) and taking into 






carbon sources to the fermentation when the glucose 
level decreased below 5% of the initial concentration, 
different regimes for batch-wise addition of glucose syrup 
were carried out (Figure 5). All the tested regimes 
increased rifamycin B from 7.5 g/l to a yield ranging from 
12.94 g/l to 13.81 g/l (72% to 84%), and the highest 
antibiotic production was achieved by addition of 5% 
glucose syrup to F2m3 medium at day 4 with a further 
increase to 14.25 g/l (90%) upon controlling DO (Figure 
6). The use of this regime thus, attained two goals: 
lowered cost and higher yield. Therefore, in all 
subsequent experiments this regime was used. The use 
of the two regimes: initial 7.5% then 5% glucose syrup 
added at day 4, and initial 5% then two increments of 5% 
glucose syrup added at days 4 and 6, led to a lower yield 
compared to that obtained upon using initial 5% then one 
increment of 5% glucose syrup at day 4. It seems that 
glucose syrup in concentrations above 10%, used in two 
or three increments, might contain some undesirable 
ingredients such as hydroxyl-methyl furfural, which may 
lead to inhibition of rifamycin B biosynthesis and/or 
biomass formation. An interesting finding is that the 
addition of the third increment of 5% glucose syrup, 
although increasing the apparent rate of production from 
day 6 to 7, caused abrupt cessation of production 
thereafter along with reduction of the biomass (Figure 5). 
By the addition of the optimum concentration of yeast 
extract (0.1%) previously determined by El-Tayeb et al. 
(2004a) to F2m3, rifamycin B production increased from 
7.5 to 15.35 g/l (105%) with a further increase to 16.3 g/l 
(117%) upon controlling DO (Figure 6). The batch-wise 
addition of 3%  soytone to F2m3 medium (Figure 6) 
increased the yield from 7.5 to 16.2 g/l (116%), by 
extending the fermentation period to 10 days the yield 
reached 17.9 g/l (139%). An integrated fermentation 
process was carried out combining all of the following 
optimized conditions: controlled DO (1 vvm for 3 days 
then 30% of saturation to the end of fermentation), 
controlled pH (6.5 for 3 days then 7.0 to the end of 
fermentation), the addition of 0.1% yeast extract at day 2, 
of 3% soytone at day 3 and of 5% glucose syrup at day 4 
to F2m3 medium. These conditions afforded a yield of 
17.43 and 19.4 g/l in days 8 and 10, respectively (Figure 
7).  
In conclusion, through improvement of the fermentation 
process, this work achieved its target where the yield of 
rifamycin B increased from 7.5 g/l to 17.43 g/l (132%) and 
by extending the fermentation period to 10 days the yield 
reached 19.4 g/l (159%). Although higher yields are 
achieved by extending the fermentation period to more 
than 8 days, sufficient economic studies on the cost of 
labor, power, etc. must be carried out to determine 
whether the extension of the fermentation period is 
beneficial or not. A comparable yield (19.11 g/l) was 
reported by Jin et al. (2002) in fed-batch fermentation in 
60,000 L fermentor with a mutant industrial strain of A. 
mediterranei.  




Further process optimization by examination and analysis 
of the kinetics of the process through mathematical 
modeling and/or genetic analysis and modification of the 
strain would most certainly further increase the yield and 
quantitatively define the process to a level which could be 
tested on a pilot scale and hence suites the design of an 
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